Scilex Holding Company
SCLXHealthcareNASDAQDrug Manufacturers - General · Last scanned Sep 5, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Scilex Holding Company focuses on Drug Manufacturers - General services and products. Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Valued at $38.1M, SCLX is a micro-cap name in its sector. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Market Cap
$38.1M
Beta
1.72
P/E (TTM)
—
P/E (Fwd)
7.42
EPS (TTM)
$-50.20
EPS (Fwd)
$0.73
ROE
—
ROA
-105.8%
Cash
$581,000
Total Debt
$106.0M
Free CF
-$8.8M
52W Change
-61.8%
Annual Financials
Cash vs Debt
Where SCLX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SCLX finished 4.97% below its 150-day moving average ($5.63) and 18.69% below its 200-day moving average ($6.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SCLX overbought or oversold?
At the September 3, 2026 close, SCLX's RSI(14) was 12.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, SCLX has $581K in cash with $106.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$8.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has been uneven over recent years, ranging from $38.0M to $30.3M.
A beta of 1.72 means SCLX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Scilex Holding Company carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Scilex Holding Company and its sector.